Jennifer Nauman
Nurse Practitioner · Columbus, OHNPI 1265087506
Payments from drug & device makers
Across 237 payments — averaging $24.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$2K
- Gilead$1K
- AbbVie$391
- Merck$324
- Lilly USA, LLC$321
- Johnson & Johnson$222
- plus $945 from 14 others
What the payments were for
- Food & beverage$5,868100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 93 | $2,194 |
| Gilead | 48 | $1,482 |
| AbbVie | 16 | $391 |
| Merck | 14 | $324 |
| Lilly USA, LLC | 13 | $321 |
| Johnson & Johnson | 11 | $222 |
| Napo Pharmaceuticals Inc | 5 | $145 |
| Theratechnologies Inc. | 7 | $130 |
| Novo Nordisk | 7 | $114 |
| Otsuka America Pharmaceutical, Inc. | 6 | $114 |
| Organon | 1 | $78 |
| Verity Pharmaceuticals Inc. | 3 | $72 |
| Antares Pharma, Inc. | 3 | $62 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $55 |
| EMD Serono, Inc. | 2 | $52 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $39 |
| Exact Sciences | 1 | $25 |
| Corcept Therapeutics | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,878 in reported general payments places this provider in the 95th percentile of 4,700 nurse practitioner providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DescovyEmtricitabine/Tenofov Alafenam | 12 | $25,786 |
| MounjaroTirzepatide | 17 | $17,889 |
| JardianceEmpagliflozin | 14 | $6,993 |
| EntrestoSacubitril/Valsartan | 13 | $6,169 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 32 | $1,065 |
| Estradiol (Twice Weekly)Estradiol | 13 | $852 |
| Estradiol | 19 | $332 |
| Doxycycline Hyclate | 15 | $324 |
| Rosuvastatin Calcium | 12 | $269 |
| Fluticasone Propionate | 27 | $207 |
| Gabapentin | 24 | $197 |
| Tizanidine Hcl | 17 | $167 |
| Finasteride | 17 | $152 |
| Hydroxyzine Hcl | 15 | $144 |
| Duloxetine Hcl | 29 | $127 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadDescovy | $1,482 | $25,78612 claims |
| Lilly USA, LLCMounjaro | $321 | $17,88917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,700 nurse practitioner providers in Ohio.
Other nurse practitioner in Columbus
- Katherine AlexanderColumbus$99K
- Kristine BrowningColumbus$22K
- Cynthia MilichColumbus$13K
- Dawn HaqueColumbus$11K
- Jena WilkinsonColumbus$10K
- Margaret BobonichCleveland$235K
- Mary GallagherWestlake$229K
- Sonia HissettCincinnati$179K
- Ashley TaylorNew Albany$107K
- Beth FaimanCleveland$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.